Daohong Zhou

Daohong Zhou, M.D.

Professor And The Henry E. Innes Professorship Of Cancer Research

Department: Pharmacodynamics
Business Phone: (352) 294-8952
Business Email: zhoudaohong@cop.ufl.edu

About Daohong Zhou

Dr. Daohong Zhou is a Professor in the Department of Pharmacodynamics at the College of Pharmacy and a Professor in the Department of Radiation Oncology at the College of Medicine, University of Florida (UF) at Gainesville. He serves as the Associate Director for Translation and Drug Development and the Henry E. Innes Professorsip of Cancer Research at the UF Health Cancer Center. Dr. Zhou received his medical (1978-1983) and graduate (1983-1986) training from Yunyany Medical College of Tongji Medical University and Henan Medical University, respectively; and his postdoctoral training (1990-1992) at the Johns Hopkins University School of Medicine. Before he joined UF in 2018, he was a Professor of Pharmaceutical Sciences and the Deputy Director of the Division of Radiation Health at the College of Pharmacy and the Associate Director for Basic Research at the Winthrop P. Rockefeller Cancer Institute in the University of Arkansas for Medical Sciences (UAMS).

Dr. Daohong Zhou has published more than 100 peer reviewed scientific articles and book chapters. His research has been well supported by grants from various private and government funding agencies, including the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Disease (NIAID). Dr. Daohong Zhou serves on several national and international peer review panels and as a reviewer for various scientific publications. He was a regular member of the Radiation Therapeutics and Biology Study Section at the National Institutes of Health (NIH). He is a Councilor of the Radiation Research Society (http://www.radres.org) and a co-founder of Unity Biotechnology (http://unitybiotechnology.com), a biotech that develops senolytic drugs for aging and age-related diseases.


Henry E. Innes Professorsip of Cancer Research
2018-Current · University of Florida
Established Investigator of Year Award
2016 · The Arkansas Biosciences Institute
The Winthrop Rockefeller Endowed Chair for Leukemia and Lymphoma Research
2010-2018 · University of Arkansas for Medical Sciences
2010-2018 · Arkansas Research Alliance

Research Profile

Dr. Zhou’s research has been focused on investigation ofthe long-term effects of genotoxic stress/DNA damage induced by ionizing radiation (IR) and chemotherapy on hematopoietic stem cell (HSC) self-renewal and genomic stability; and the role of HSC injury in IR- and chemotherapy-induced long-term bone marrow suppression and leukemogenesis. His studies has led to a better understanding of the cellular and molecular mechanisms by which IR and chemotherapy cause normal tissue damage and the discovery of the first potent and broad-spectrum senolytic drug, ABT263-a specific Bcl-2/xl inhibitor, that can selectively kill senescent cells to rejuvenate both prematurely senescent tissue stem cells induced by IR and tissue stem cells in normally aged mice. This discovery may lead to new therapeutics for various age-related diseases and the side effects induced by chemotherapy and IR. More recently, he developed several proteolysis targeting chimeras (PROTACs) that can target Bcl-xl and other proteins of interest for degradation via the ubiquitination and proteasome system. He found that Bcl-xl PROTACs can selectively induce Bcl-xl degradation in senescent cells and various cancer cells but not in platelets, suggesting that Bcl-xl PROTACs have the potential to be developed as a better senolytic and anticancer agent than ABT263 by not causing thrombocytopenia. Using the PROTAC drug development platform, he is developing additional specific antitumor agents.


2019 Translational research : the journal of laboratory and clinical medicine
2017 Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
2015 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2011 International journal of hematology


Sep 2020 ACTIVE
Identifying Novel Senolytic Agents and Molecular Targets
Jun 2020 ACTIVE
Intercollaborative Radiation Countermeasure Consortium (INTERACT Consortium) for advanced development of medical countermeasures (MCM) to mitigate/treat acute and delayed radiation syndromes
Jun 2020 ACTIVE
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
UNIV OF MARYLAND BALTIMORE · Principal Investigator
Apr 2020 ACTIVE
Inhibition of Bcl-xL by Targeted Degradation
Sep 2019 ACTIVE
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer
NATL INST OF HLTH NCI · Principal Investigator
Aug 2019 ACTIVE
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics
NATL INST OF HLTH NIA · Principal Investigator
Sep 2018 – Feb 2020
Cancer Therapy-induced Long-term Bone Marrow Injury
NATL INST OF HLTH NCI · Principal Investigator
Sep 2018 – Aug 2020
NCI Clinical and Translational Exploratory/ Developmental Studies
Aug 2018 – Aug 2019
Discovery and Target Identification of Senolytic Agents
Jul 2018 ACTIVE
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis
NATL INST OF HLTH NCI · Principal Investigator
Jun 2018 – May 2019
The 4th International Cell Senescence Association (ICSA) meeting (ICSA 2018) Resubmission
NATL INST OF HLTH NIA · Principal Investigator
Apr 2018 ACTIVE
Ionizing radiation induced hematological malignancies
NATL INST OF HLTH NCI · Principal Investigator


1986 · Henan Medical University
1982 · Yunyang Medical College

Contact Details

(352) 294-8952